Impact of Recent Trends on Next Generation Sequencing Market

Next generation sequencing (NGS) accelerates molecular biology research process by providing automation, speed, and flexibility. The technology has been widely applied in the research and development of personalized medicine, oncology research, HLA typing, biomarker research, and various others. Due to its wide scope of application and in-depth results, it has been rapidly accepted by the research groups. Various service providers have also emerged to provide consultation and next generation sequencing services. This has made the technology accessible to more number of research projects, as researchers who did not have skills and expertise in high throughput sequencing also contributed to market growth. In 2013, The U.S. FDA approved Illumina next generation sequencing system for its application in diagnosis.

Majority of the market has been dominated by 3 major players - Illumina, Thermo Fisher Scientific and Roche. These three players account for more than 70% of the market share. According to several users, Thermo Fisher Scientific faces significant technological challenges due to lower success rate of pH-change technology observed in its sequencer. Light emission technology incorporated by Illumina has however provided competitive edge. Roche has made series of acquisitions to gain control over the next generation sequencing market. In 2014, the company acquired Genia Technologies and Bina Technologies, and later in 2015, it acquired Kapa Biosystems to strengthen next-generation sequencing product offerings. In 2016, Thermo Fisher Scientific also made an offer of over USD 30 Bn for acquisition of Illumina, Inc.; however there is no report of Illumina accepting the offer. Complete Genomics, Genapsys, GnuBio, Lasergen, NabSys, Noblegen Biosciences, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Stratos Genomics are other players in the next generation sequencing market.

Free Sample Report@ http://www.sa-brc.com/Global-Next-Generation-Sequencing-Market-Assessment--Forecast-2017-2021/up52

Due to lack of knowledge and skills, trend for outsourcing of NGS projects to service providers is expected to grow rapidly. This is evident from the surge in funding for genetic research, and prosperity of next gen. seq. service providers. The U.S. currently has the largest number of next generation sequencing service providers. North America and Europe lead the devices segment ?owing to higher installed base, while sales of new devices is expected to increase in Asian countries. Technological innovations, government funding for genetic research, acceptance of high technology devices in medical research would support market growth in the Asia region.

Development in biopharmaceutical research and increasing success rate in genetics has encouraged scientists to take up more challenging projects. Innovative technologies such as next generation high throughput sequencing have greatly contributed to development of personalized medicines, and deeper understanding of cancer development process. Considering limitless application of this technology in the field of medical science, the next generation sequencing market for devices as well as services is expected to grow steadily in the near future.

Click For TOC@ http://www.sa-brc.com/Global-Next-Generation-Sequencing-Market-Assessment--Forecast-2016-2020/upcomingdetail52

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.